BDD21288

BDD21288 is an investigational delayed-release oral formulation of prednisone developed by BDD Pharma Ltd using its proprietary Oralis technology. The Oralis platform is designed to provide precise, timed drug release, which in the case of BDD21288 is intended to align with the circadian rhythm of inflammatory cytokines. By releasing prednisone in the early morning hours (typically around 2 AM to 4 AM) after a bedtime dose, the drug aims to optimize the management of conditions like rheumatoid arthritis, where symptoms such as morning stiffness are driven by nocturnal cytokine peaks. This chronotherapeutic approach seeks to improve efficacy and patient outcomes compared to standard immediate-release corticosteroids.